Capsugel wants to standardise lipid formulation tests

By Natalie Morrison

- Last updated on GMT

Related tags Pharmacology

Capsugel's new consortium for lipid formulation standardisation
Capsugel has launched a non-profit consortium in a bid to establish a lipid formulation classification system.

The organisation – made up of experts from industry and academia – will conduct research into oral lipid-based drug delivery systems for poorly soluble drugs.

It eventually hopes to develop guidelines to standardise in vitro​ evaluation methods to support the development of promising new drug candidates; a high proportion of which are tricky to develop because of bioavailability problems.

Speaking to, the consortium’s chair Hassan Benameur said: “Lipid formulations have been underutilised. This is mainly because the published literature on mechanisms of action, laboratory formulation methods, and development of lipid-based products is limited.​”

Benameur, who is also senior director of pharmaceutical sciences at Capsugel said a better knowledge-base will give developers more confidence when using lipid formulations.

“If formulators can predict which drugs will benefit from lipid formulations, and have appropriate tests to optimise formulations before they embark on in vivo experiments, formulators are more likely to consider lipid formulations at an early stage,”​ he said.

When asked why Capsugel took the arguably unusual move of forging a not-for-profit partnership with would-be rival firms, including Merck KGaA and Sanofi, Benameur told us it is “pre competitive”.

He said sharing the financial load, as well as creating a global consensus within both industry and with the regulators, makes sense for future business.

Sanofi research and development’s (R&D) Ross Blundell, a consortium member, also said: “It is difficult to see that an industrial partner working alone could have achieved the same breadth of data in the same time frame as the consortium.”

The latest findings

The team’s first research paper, set to be published in the Journal of Pharmaceutical Sciences, focuses on standardisation for digestion testing.

Colin Pouton from the Monash University in Melbourne – the working group leader of the Lipid Formulation Classification System Consortium – said: “Our initial findings confirm that using the digestion model is the preferable method for differentiating between formulations.”

However Benameur said there are currently too many methods - different pH's, different formulae for simulated intestinal fluid, different enzyme levels, different volumes and concentrations of materials – which is confusing to developers.

“At present the consortium is focused on establishing the variables that affect the results of in vitro dispersion and digestion tests,”​ he said. “The consortium will then produce guidelines for performing in vitro dispersion and digestion tests, including suggested standard test specifications and examples of data processing.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers